EKF Diagnostics
EKF Diagnostics Holdings plc is a UK-headquartered, AIM-listed global diagnostics company manufacturing point-of-care in-vitro diagnostic devices (hematology, diabetes, women's health, sports, veterinary), central laboratory reagents, and specialty diagnostic enzymes from US and German facilities, distributing to 120+ countries across healthcare, biotech, and life sciences customers.
- Company typePublic
- Founded1990
- HeadquartersVale of Glamorgan, United Kingdom
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What EKF Diagnostics does
EKF Diagnostics Holdings plc is a UK-domiciled, AIM-listed (LSE: EKF) global diagnostics and biotechnology company founded in 1990 and headquartered in Cardiff, Wales. The company develops, manufactures, and distributes point-of-care in-vitro diagnostic devices and life sciences products through wholly-owned operating subsidiaries including Stanbio Laboratory LLC (US, Boerne, TX), EKF-diagnostic GmbH (Germany), and Separation Technology Inc. EKF's product portfolio spans point-of-care hematology analyzers (DiaSpect Tm, Hemo Control, HemataStat II), diabetes management systems (Biosen C-Line, Quo-Test, Quo-Lab, STAT-Site WB), women's health tests (Creamatocrit Plus, QuPID, True 20), sports performance analyzers (Lactate Scout Sport), veterinary diagnostics (Lactate Scout Vet, Hemo Vet), central laboratory reagents and immunoassays (Beta-Hydroxybutyrate LiquiColor, RaPET, QuStick), molecular transport media (PrimeStore), and specialty diagnostic enzymes (Arylacylamidase, Beta-Hydroxybutyrate Dehydrogenase, Salicylate Hydroxylase). The proprietary EKF Link platform integrates point-of-care devices with hospital and laboratory IT systems for real-time data and device management.
EKF's revenue model is predominantly hardware-and-consumable sales (analyzer devices plus recurring cuvettes, reagents, and enzymes), supplemented by contract reagent manufacturing services and (post-ADL Health acquisition) COVID-19 molecular diagnostic testing services. The company distributes to over 120 countries through authorized medical supply dealers, direct distribution, and channel partners, with manufacturing sites on two continents providing regulatory and logistical reach. Group purchasing agreements such as the Blood Centers of America deal provide anchor enterprise channels, while long-tail distribution and a partner portal extend mid-market reach. Reported FY2025 revenue was £51.6M with £7.1M pre-tax profit and 51% gross margin in H2 2025, representing 3% year-over-year growth.
The company is executing a stated five-year strategic plan anchored by selective acquisitions, including Intelligent Ultrasound Group plc (February 2025) and Beep Insights AB technology assets (April 2026), to extend into adjacent medical imaging and AI-enabled sports performance verticals. Christopher Mills (Non-Executive Director) controls approximately 29.49% of voting rights through investment entities. The company is ISO 13485 and ISO 9001 certified across multiple jurisdictions and complies with AIM listing requirements, including share buyback activity to maintain the controlling stake below the 30% mandatory offer threshold.
EKF Diagnostics firmographics
Firmographics- Name
- EKF Diagnostics
- Legal name
- EKF Diagnostics Holdings plc
- Website
- https://ekfdiagnostics.com
- Company type
- Public
- Founded year
- 1990
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- EKF Diagnostics Holdings plc is a UK-headquartered, AIM-listed global diagnostics company manufacturing point-of-care in-vitro diagnostic devices (hematology, diabetes, women's health, sports, veterinary), central laboratory reagents, and specialty diagnostic enzymes from US and German facilities, distributing to 120+ countries across healthcare, biotech, and life sciences customers.
- Ownership category
- akta.pro rank
EKF Diagnostics industry classification
Industry- Product category
- Point-of-Care In-Vitro Diagnostics
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), In-Vitro Diagnostic Substance Manufacturing (325413), Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845), In Vitro & In Vivo Diagnostic Substances (2835), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
- akta.pro primary industry
- Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices) (HLACAPAK)
- akta.pro secondary industries
- Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL), Reference Laboratory Testing (Clinical Pathology & Chemistry) (HLAMADAA), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Personal Medical Devices & Home Diagnostics (Thermometers, Blood Pressure Monitors, Glucose Meters, Rapid Tests) (CRADAMAK)
Keywords
Where EKF Diagnostics is headquartered
LocationHeadquarters
- HQ city
- Vale of Glamorgan
- HQ country
- United Kingdom
- HQ region
- Europe
Offices3 records
Markets served
EKF Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Point-of-Care Diagnostic Devices: Sale of medical devices and tests for point-of-care testing including hematology, diabetes, women's health, sports performance, and veterinary analyzers
- Life Sciences Products: Reagents, enzymes, and components for research, biotechnology, and pharmaceutical industries
- Central Laboratory Products: Devices, tests, and media for high-throughput central laboratory analysis including reagents, immunoassays, and transport media
- Contract Manufacturing Services: Contract reagent services including reagent formulation and kitting for healthcare partners
Go-to-market motion2 records
Distribution channels4 records
Marketing channels3 records
EKF Diagnostics product offering
Product offeringCore offering
EKF Diagnostics manufactures and distributes point-of-care in-vitro diagnostic devices and tests for hematology, diabetes, women's health, sports performance, and veterinary applications, alongside central laboratory reagents and life sciences diagnostic enzymes. The company also supplies the EKF Link IT platform connecting point-of-care analyzers to hospital and laboratory information systems. Products are manufactured at facilities in the USA and Germany and sold to healthcare providers, blood centers, life sciences companies, and authorized dealers in over 120 countries.
Product overview
EKF Diagnostics is a global diagnostics and biotechnology company offering point-of-care in-vitro diagnostic devices and tests alongside life sciences products. The portfolio includes point-of-care analyzers for hematology (DiaSpect Tm, Hemo Control, HemataStat II), diabetes management (Biosen C-Line, Quo-Test, Quo-Lab, STAT-Site WB), women's health (Creamatocrit Plus, QuPID, True 20), and sports/veterinary applications (Lactate Scout Sport, Lactate Scout Vet, Hemo Vet). The connectivity platform EKF Link enables integration with hospital IT systems. Central laboratory offerings comprise reagents (Beta-Hydroxybutyrate LiquiColor), immunoassays (RaPET), infectious disease tests (QuStick), occult blood tests (Hema-Screen), transport media (PrimeStore), and analyzers (Uri-Trak 120M). Life sciences products include precision fermentation services, diagnostic enzymes (Arylaclamidase, Beta-Hydroxybutyrate Dehydrogenase, Salicylate Hydroxylase), and contract reagent manufacturing. Manufacturing facilities are located in the USA and Germany, with products distributed to over 120 countries worldwide.
Differentiator
Problem solved
Functional benefit
Products and services
- DiaSpect Tm
Quantifiable outcome
- 3% revenue increase in 2025
- +3 more outcomes
Companies that use EKF Diagnostics
Customer profileNamed customers2 records
Segments7 records
Ideal customer profiles4 records
EKF Diagnostics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration2 records
Feature5 records
EKF Diagnostics partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- Blood Centers of AmericacoreEKF Diagnostics signed a three-year group purchasing agreement with Blood Centers of America, gaining access to more than 60 independent community blood centers across the US. Under the deal, EKF will supply its DiaSpect Tm hand-held haemoglobin analyser, consumable cuvettes, and the EKF Link IT system for quality control and data management. This agreement is a significant milestone in the company's five-year strategic plan to become the global leader in point-of-care hematology testing.
- Intelligent Ultrasound Group plccoreEKF Diagnostics acquired Intelligent Ultrasound Group plc in February 2025. CFO Helen Jones will oversee post-acquisition integration as the company executes its five-year development plan for accelerated growth.
- Advanced Diagnostic Laboratory LLC (ADL Health)minorEKF Diagnostics acquired Advanced Diagnostic Laboratory LLC (ADL Health), a Texas-based molecular diagnostics testing laboratory, specializing in COVID-19 testing for corporate, government, and travel sectors, providing rapid and accurate results including through high throughput PCR testing.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
EKF Diagnostics competitors and assessment
Company assessmentDirect peers
- HemoCue (Danaher): Direct competitor in point-of-care hemoglobin testing. HemoCue's handheld Hb analyzers and microcuvettes compete head-to-head with EKF's DiaSpect Tm in blood banks, anemia screening, and primary care settings globally.
- Nova Biomedical: Direct peer in hospital-grade POC glucose and lactate analyzers; Nova's StatStrip and Lactate Plus overlap with EKF's Biosen C-Line and Lactate Scout Sport, and the company serves the same clinical and sports performance segments.
- Trinity Biotech: AIM/Nasdaq-listed POC diagnostics peer focused on HbA1c and hemoglobin diagnostics; Trinity's Ultra2 and Premier Hb9210 analyzers compete directly with EKF's Quo-Test, Quo-Lab, and Hemo Control product lines.
- ARKRAY: Japanese POC diagnostics manufacturer with overlapping HbA1c and urine analytics portfolio (Quotation series) that competes with EKF's Quo-Test/Quo-Lab HbA1c analyzers globally.
- PTS Diagnostics (Trividia Health): POC diagnostics company selling HbA1c (A1cNow+) and lipid/CRP panels with overlapping customers and channels in primary care and pharmacy settings; competes with EKF's Quo-Lab and STAT-Site product lines.
Broad incumbents
- Siemens Healthineers (POC): Large incumbent with a broad POC and central-lab diagnostics portfolio including blood gas, HbA1c, and urine analyzers that overlap with EKF's Uri-Trak 120M, Quo-Test, and central lab reagents.
- Abbott Point of Care: Broader POC diagnostics incumbent (i-STAT, FreeStyle Libre) competing with EKF in glucose, lactate, and decentralized hospital testing; serves the same clinician customer base with greater commercial reach.
- QuidelOrtho: Broad infectious disease and rapid diagnostics player whose Sofia and Triage product lines overlap with EKF's central laboratory infectious disease and immunoassay products (QuStick, RaPET, Hema-Screen).
- GE HealthCare (Ultrasound): Adjacent peer through EKF's recent acquisition of Intelligent Ultrasound Group; GE competes in clinical ultrasound simulation and AI-enabled imaging — a category EKF is now exposed to post-acquisition.
Emerging players
- Sinocare: Chinese POC blood glucose leader expanding into HbA1c and lactate; overlaps with EKF's diabetes and lactate franchises in price-sensitive global markets and represents a low-cost competitive threat.
Market position
Weaknesses1 record
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
EKF Diagnostics social profiles
Digital presenceEKF Diagnostics compliance and trust
Trust signalCompliance2 records
EKF Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
EKF Diagnostics leadership team
Management profileNumber of profiles
Profiles10 records
EKF Diagnostics subsidiaries and ownership
Company hierarchySubsidiaries3 records
EKF Diagnostics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
EKF Diagnostics M&A and investment
M&A and investmentM&A9 records
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about EKF Diagnostics
What does EKF Diagnostics do?
EKF Diagnostics manufactures and distributes point-of-care in-vitro diagnostic devices and tests for hematology, diabetes, women's health, sports performance, and veterinary applications, alongside central laboratory reagents and life sciences diagnostic enzymes. The company also supplies the EKF Link IT platform connecting point-of-care analyzers to hospital and laboratory information systems. Products are manufactured at facilities in the USA and Germany and sold to healthcare providers, blood centers, life sciences companies, and authorized dealers in over 120 countries.
Is EKF Diagnostics a public or private company?
EKF Diagnostics is a public company. It is classified as public and is currently operating.
When was EKF Diagnostics founded?
EKF Diagnostics was founded in 1990. It employs 101 to 250 people.
Where is EKF Diagnostics based?
EKF Diagnostics is headquartered in Vale of Glamorgan, United Kingdom, in the Europe region.
How does EKF Diagnostics make money?
Four revenue lines are on record. Point-of-Care Diagnostic Devices are the primary driver. The others are life Sciences Products, central Laboratory Products and contract Manufacturing Services.
Who are EKF Diagnostics's main competitors?
Direct peers on record are HemoCue (Danaher), Nova Biomedical, Trinity Biotech, ARKRAY and PTS Diagnostics (Trividia Health). Broad incumbents are Siemens Healthineers (POC), Abbott Point of Care, QuidelOrtho and GE HealthCare (Ultrasound). Sinocare is listed as an emerging player.
Does EKF Diagnostics have an API?
No public API is recorded for EKF Diagnostics.
What industry is EKF Diagnostics in?
EKF Diagnostics's product category is Point-of-Care In-Vitro Diagnostics. Its primary akta.pro industry code is HLACAPAK, Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices), with a secondary code of HLAHACAL, Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers). Its NAICS code is 334510 and its SIC code is 3841.